Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

Hatanaka, Takeshi; Yata, Yutaka; Naganuma, Atsushi; Kakizaki, Satoru.

Afiliação

Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan.
Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, Japan.
Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.
Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.

Cancers (Basel) ; 15(6)2023 Mar 16.

Article em En | MEDLINE | ID: mdl-36980684

Palavras-chave

TACE inappropriate; TACE refractory; atezolizumab plus bevacizumab; conversion therapy; durvalumab plus tremelimumab; hepatocellular carcinoma; immune checkpoint inhibitor; intermediate-stage hepatocellular carcinoma; molecular-targeted therapy; transarterial chemoembolization; tyrosine kinase inhibitor; up-to-7 criteria

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article